Compare · LHDX vs LIVN
LHDX vs LIVN
Side-by-side comparison of Lucira Health Inc. (LHDX) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LHDX and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $3.51B, about 17.0x LHDX ($206.3M).
- LIVN has hit the wire 1 time in the past 4 weeks while LHDX has been quiet.
- LIVN has more recent analyst coverage (20 ratings vs 0 for LHDX).
- Company
- Lucira Health Inc.
- LivaNova PLC
- Price
- $0.45-19.60%
- $64.17-0.02%
- Market cap
- $206.3M
- $3.51B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 1
- Recent ratings
- 0
- 20
Lucira Health Inc.
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest LHDX
- SEC Form 15-12G filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Bankruptcy or Receivership
- SEC Form NT 10-Q filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form NT 10-K filed by Lucira Health Inc.
Latest LIVN
- Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
- SEC Form 4 filed by Tezel Ahmet
- SEC Form 4 filed by Poletti Franco
- SEC Form 4 filed by Makatsaria Vladimir
- SEC Form 4 filed by Shvartsburg Alex
- SEC Form 4 filed by Bolton Stephanie
- SEC Form 4 filed by Kozmina Natalia
- MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
- LivaNova to Announce First-Quarter 2026 Results
- LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea